Price of Multiple Sclerosis Disease Modifying Therapies Keeps Creeping Up

May 22nd, 2023|Categories: Featured, Industry News|Tags: , , , , |

Disease modifying therapies (DMTs) for multiple sclerosis (MS) have a significant positive impact on patient outcomes but are often expensive. A recent report by GlobalData finds that prices for MS DMTs are on a steady increase, with drugs like Tysabri by biogen or Gilenya by Novartis increasing by 12%. This impacts patients, according to many experts.

Biogen Settles MS Kickback Suit for $900M

July 20th, 2022|Categories: Featured, Industry News|Tags: , , , , |

Biogen has settled a whistleblower suit regarding kickbacks for its line of multiple sclerosis (MS) drugs. The company was sued for allegedly paying clinicians kickbacks when they prescribed its drugs Tecfidera, Tysabri, and Avonex. The settlement comes as competition from Novartis and Ocrevus closes in on Biogen’s MS drugs

Go to Top